GSTT1, Calpain 10 SNP 19 and indices of glycaemia in type 2 Diabetes.

GSTT1, Calpain 10 SNP 19 and indices of glycaemia in type 2 Diabetes. Br J Biomed Sci. 2019 Aug 28; Authors: Osman H, Osman MY, Alsaidy AA PMID: 31460838 [PubMed - as supplied by publisher]
Source: British Journal of Biomedical Science - Category: Laboratory Medicine Tags: Br J Biomed Sci Source Type: research

Related Links:

- Collaboration combines Abbott ′s world-leading glucose sensing technology with Omada Health's best-in-class, proprietary digital coaching platform to provide personalized, on-the-go care
Source: - Category: Pharmaceuticals Source Type: news
Abbott (NYSE: ABT) and Omada Health announced today they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) technology, with Omada Health's pioneering digital care program, aiming to create a new paradigm for people with Type 2 diabetes.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Abbott Business and Industry Source Type: news
TYPE 2 diabetes requires careful monitoring to ward off the risk of rising blood sugar levels. Certain dietary choices have been shown to control blood sugar levels, including a certain seed.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
The most clinically relevant new aspects of the 2019 version of the ESC Guidelines compared with the previous version published in 2013 relate to:Reclassification of cardiovascular (CV) risk.Individualized blood pressure (BP) targets.New lipid targets relating to severity of CV risk.Recommendations for the use of PCSK9 inhibitors in lipid management.New recommendations regarding the role of aspirin and the novel oral anticoagulants (NOACs) in diabetes.New recommendations for the duration of dual antiplatelet therapy post-ACS in diabetes mellitus (DM).The interpretation of the CV outcome trials in diabetes therapies and the...
Source: European Heart Journal - Category: Cardiology Source Type: research
S Karthik, PE Joseph, T BabuJournal of Postgraduate Medicine 2019 65(4):244-246 Dipeptidyl peptidase-4 inhibitors (DPP-4i) are one of the mainstay drugs in the management of type 2 diabetes mellitus. It has been well-documented that these class of drugs cause allergic reactions. Bullous pemphigoid (BP) is a blistering skin condition commonly associated with many drugs. Here, we report a case of probable DPP-4i-induced BP in an elderly man, which resolved on discontinuation of the drug. Although this adverse drug reaction has been documented in Western world and Japanese ethnicity, this seems to be the first case report of...
Source: Journal of Postgraduate Medicine - Category: Internal Medicine Authors: Source Type: research
The article Insulin glargine/lixisenatide in type 2 diabetes: a profile of its use, written by Emma Deeks, was originally published Online First without Open Access.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research
ConclusionStudies on arthroplasty survival should systematically mention gender and diabetes status and beware of potential group incomparability.Level of evidenceIII, cohort study.
Source: Orthopaedics and Traumatology: Surgery and Research - Category: Orthopaedics Source Type: research
TYPE 2 diabetes requires careful monitoring to keep the threat of rising blood sugar levels at bay. Certain foods have been shown to lower blood sugar levels, including a certain fruit.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Metformin, the first choice drug for type 2 diabetes treatment in all stages of therapy, and one of the most widely prescribed anti-hyperglycemic agent worldwide, represents a rare example of an old drug which continues to display new beneficial effects in various fields. However, lactic acidosis (LA) persists as a serious adverse effect. LA incidence is low and is not necessarily determined by the administration of metformin. Unfortunately, the concern for this complication has negatively affected the drug use, particularly in chronic kidney disease, which may impair drug excretion, and in congestive heart failure and chr...
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research
More News: Biomedical Science | Diabetes | Diabetes Type 2 | Endocrinology | Laboratory Medicine | Science | UK Health